156 results about "Potentiator" patented technology

The invention discloses an immunogenic composition containing an adjuvant as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises self-assembled gE virus-like nanoparticles, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the self-assembled gE virus-like nanoparticles are formed by polymerizing and assembling monomers; the monomers include VZV gE, a linker peptide (SGS), and a VZV gI polypeptide containing a Th epitope. The immunogenic composition can be applied to varicella-zoster virus vaccines, and solves the technical problems of weak gE immunogenicity and serious vaccine side reaction in vaccines prepared in the prior art. The immunogenicity of the vaccine is equivalent to that of the Xinanlii, and the use of an immunopotentiator in the vaccine can be reduced, so that the clinical side reaction of the vaccine is lower; in addition, the vaccine can induce a gI specific antibody and gI specific CMI reaction, and the effectiveness of the vaccine can be further improved. In short, the immunogenic composition has good clinical application potential.

The invention belongs to the technical field of vaccine adjuvants, and particularly relates to a water-in-oil-in-water adjuvant, a veterinary vaccine and a preparation method thereof.The water-in-oil-in-water adjuvant is prepared from, by weight, 0.5%-7.5% of a hydrophilic composite surfactant, 0.6%-9.8% of an oleophylic composite surfactant, 70%-85% of mineral oil and the balance water; and the mineral oil also comprises the following components in concentration: a reinforcing agent of 0.45-0.9 g / ml and a stabilizing agent of 2-6.9 g / L, wherein the water-in-oil-in-water adjuvant forms a gelatinous structure under the regulation of the stabilizer and is a non-Newtonian fluid of which the viscosity is not higher than 25cp; the adjuvant shows the non-flowing fluid characteristic through the stabilizer, the rheological property of the produced vaccine is enhanced, the stability of the vaccine is improved, on the premise that the hydrophilic surfactant and the oleophylic surfactant are balanced, the natural polymer enhancer is added, and on the premise that the adjuvant viscosity is reduced and granuloma side reaction is not prone to being generated, the stability of the vaccine is improved. Short-term immunity and long-term immunity can be induced at the same time, and the application of the water-in-oil-in-water adjuvant in the field of veterinary vaccines is expanded.

The present disclosure provides compounds, compositions, and methods for treating or preventing neurological disorders in a patient. The disclosed methods include administration to a subject suffering from a neurological disorder of a compound disclosed herein.

The invention discloses an immunogenic composition containing a composite adjuvant as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises a gE-gI fusion protein, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the gE-gI fusion protein comprises a VZV gE, a connecting peptide and a VZV gI. The immunogenic composition provided by the invention only contains one immunopotentiator, can be applied to VZV vaccines, and solves the problems of relatively weak gE immunogenicity and relatively large clinical side reaction of the vaccines prepared in the prior art. The immunogenicity of the vaccine is equivalent to that of the Xinanlii, but the vaccine contains fewer immunopotentiators and has lower clinical side effects; in addition, the vaccine can also induce a gI specific antibody and gI specific CMI reaction, which is beneficial to further improvement of the effectiveness of the vaccine. In short, the immunogenic composition has good clinical application potential.

The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a milk thistle extract or powder. The invention also relates to the combination of a sulforaphane or a derivative thereof and a milk thistle extract or powder. The invention also relates to the combination of a broccoli extract or powder and a milk thistle extract or powder. The invention provides compositions and methods relating to these combinations.

To provide the use of a CBR1 agonist as an adjuvant and an adjuvant composition.SOLUTION: A compound represented by formula (1): Wherein R represents a cyclopropyl group or a 2-chloroethyl group. The antibody induction-promoting agent contains a compound represented by general formula (I) as an active ingredient.SELECTED DRAWING: None

The invention belongs to the technical field of chemiluminescence immunoassay, and particularly relates to application of a luminescence retarder in improving development quality of solid-phase membrane immunodetection. According to the invention, when the concentration of the delay agent is fixed, the time of luminescence starting delay and the concentration of the enzyme catalyst are in nonlinear negative correlation, that is, the delay time is obviously increased along with the reduction of the enzyme concentration. The nonlinear negative correlation is suitable for luminescent systems of different reinforcing agents. Benefited from the enzyme concentration dependent luminescence delay effect, the chemiluminescence liquid with the delay effect is used for improving the development quality of solid-phase membrane immunodetection for the first time, noise and background signals are suppressed, and the chemiluminescence liquid has wide application value in the aspect of solid-phase membrane immunodetection.

GD2 specific chimeric antigen receptor effector cells for the treatment of solid tumors, possibly in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor. The invention relates to a GD2-specific chimeric antigen receptor (GD2. CAR) effector cell for use in the treatment of solid tumors, in particular in the treatment of extracranial GD2 + tumors, such as soft tissue sarcoma and osteosarcoma, neuroblastoma, melanoma, lung cancer, bladder cancer and retinoblastoma, and brain tumors. In addition, the present invention also relates to the use of the GD2. CAR genetically modified effector cell in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor for the treatment of solid tumors.

The present invention describes the synthesis and biological evaluation of new substituted pyridine derivatives as foxj1 activity enhancers. In embodiments, novel pyridine derivatives were synthesized and the ability thereof to enhance foxj1 activity was evaluated. The novel pyridine derivatives synthesized in the present invention not only exhibited excellent activity but also exhibited excellent metabolic safety and pharmacokinetic profile in a Tg (foxj1: egfp) transgenic zebrafish animal model. In addition, the novel pyridine derivatives synthesized in the present invention enhanced cilia-promoting capability in a motile ciliated cell differentiation experiment in which mouse tracheal epithelial cells (mTECs) were isolated from the airways of mice and cultured by ALI. As a result, a series of foxj1 activity enhancers with substituted pyridine skeleton has the potential to be developed as preventive and therapeutic agents for respiratory diseases.

Disclosed herein, in some aspects, are methods of treating autoimmune diseases or conditions using TCR targeting molecules or cells expressing TCR targeting molecules. TCR targeting molecules can comprise a moiety that binds to a TCR variable beta chain (TCRBV) or a TCR variable alpha chain (TCRAV). TCR targeting molecules can further comprise one, two or all of: (ii) an immune cell engager; (iii) a cytokine inhibitor molecule; (iv) a cytotoxic agent; and / or (v) a death receptor signal enhancer. Additionally, disclosed herein, in some aspects, are nucleic acids encoding the same, and methods of producing the aforesaid molecules.

The invention relates to the technical field of biological medicine, in particular to application of flufenamic acid in preparation of a polymyxin E antibacterial synergist. The invention discloses an application of flufenamic acid in preparation of a polymyxin E antibacterial synergist, the flufenamic acid has no obvious antibacterial effect on salmonella when being independently used, but the flufenamic acid and polymyxin E can enhance the antibacterial activity of the polymyxin E on the salmonella and reduce the use dosage of the polymyxin E when being jointly used in and out of an animal body, so that the antibacterial effect of the polymyxin E on the salmonella can be enhanced. The antibacterial activity of the polymyxin E on salmonella is enhanced, and the drug resistance of the polymyxin E is inhibited. Flurfenamic acid is approved to be used for other purposes as FDA, and when the flurfenamic acid is combined with polymyxin E, the flurfenamic acid has the characteristic of high safety, and meanwhile, the generation of the drug resistance of the polymyxin E drugs can be effectively avoided. The invention provides a basis for mining a new antibacterial prevention and control strategy for the polymyxin E drug-resistant bacteria.

A noninvasive ophthalmic formulation, comprising a chelator (such as EDTA and its salts), a transport enhancer (such as Methyl Sulfonyl Methane; MSM), a second polyoxyalkylene permeation enhancer such as propylene glycol capable of enhancing permeation through lipid-thickened ocular membranes, a thickening agent such as hydroxyethyl cellulose (HEC) and a surfactant such as polysorbate 80, is provided. The novel combination of the ingredients unexpectedly and beneficially reduces symptoms associated with early-stage, age-related cataracts. Methods for treating cataracts with compositions of the invention and measurement of improved visual function by measuring contrast sensitivity (CS) are provided.

The invention belongs to the technical field of medical dressings, and particularly relates to a gel dressing for relieving postoperative lymphedema of breast cancer and a preparation method thereof.The gel dressing is prepared from, by weight, 0.1-0.5 part of active medicine, 8-12 parts of modified matrix, 0.2-0.8 part of dopamine hydrochloride, 2 parts of dispersing agent and 0.5-1.5 parts of enhancer, menthol with functions of promoting infiltration and inducing diuresis to alleviate edema is used for modifying mussel mucoprotein with good biocompatibility, the crosslinking gelling property of the mussel mucoprotein is improved, meanwhile, along with hydrolysis breakage of covalent bonds, gel slowly collapses to release active drugs, and the active drugs and the menthol cooperate with each other, and the postoperative lymphedema of breast cancer is treated from various mechanism ways.

The invention discloses an HRP chemiluminescent substrate system, a kit and a preparation method, the HRP chemiluminescent substrate system is composed of a liquid A and a liquid B which are physically isolated and stored; the solution A is an alkaline buffer system with the pH value of 9.0-9.6, and comprises isoluminol or a salt substrate thereof, a cationic surface active agent CTAC and a metal chelating agent diethylene triamine pentaacetic acid; and the solution B is an acidic solution with the pH value of 4.5-5.5, and comprises an oxidizing agent and a reinforcing agent N-(3-chloro-4-hydroxyphenyl) acetanilide. According to the invention, the reinforcing agent N-(3-chloro-4-hydroxyphenyl) acetanilide is placed in the acidic liquid B, when the acidic liquid B is mixed with the alkaline liquid A, the mixed system is maintained at a specific pH value of 8.3-8.6, and the reinforcing agent is rapidly dissociated into phenoxy anions; and carrying out in-situ capture and enrichment on a micelle interface by CTAC cationic micelles with positive charges, which exist in the solution A in advance, through electrostatic attraction. And in cooperation with a low-ion-strength environment brought by no buffer salt in the liquid B, the system ensures the high activity of the HRP enzyme, realizes directional interface catalysis of the enhancer, and significantly improves the luminous efficiency and stability.

The present application relates to viral sensitizers. More specifically, the present application relates to inhibitors of PDKP1, as well as methods of using such compounds as viral sensitizers, specifically for increasing permissiveness of a cell to the production of virus from reverse genetics systems, replicating viruses and increasing transduction.

The invention discloses an immunogenic composition containing gE virus-like nanoparticles as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises gE virus-like nanoparticles, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the gE virus-like nanoparticles comprise VZV gE, a linker peptide (SGS) and a VZV gI polypeptide containing a Th epitope. The immunogenic composition provided by the invention can be applied to VZV vaccines, and solves the technical problems of weak gE immunogenicity and serious vaccine side reaction in vaccines prepared in the prior art. The immunogenicity of the vaccine is better than that of Xinanliei, the use of an immunopotentiator is reduced, and the clinical side reaction is lower. In addition, the vaccine can also induce an obvious gI specific antibody, which is beneficial for further improving the effectiveness of the vaccine. In short, the immunogenic composition provided by the invention has good clinical application potential.

The invention belongs to the technical field of molecular biology, and provides a reinforcing agent for improving amplification efficiency of mismatched primers in PCR (polymerase chain reaction), a reaction system and application of the reinforcing agent. The reaction system is a liquid reaction system and comprises a reinforcing agent, Trisma, dNTP (deoxyribonucleoside triphosphate), MgCl2, NH4Cl, KCl, BSA (bovine serum albumin), glycerol, betaine, a specific primer, a DNA (deoxyribonucleic acid) template, DNA polymerase, DMSO (dimethylsulfoxide) and water. The invention also provides an application of the enhancer in gene polymorphism detection by a PCR-RFLP (Polymerase Chain Reaction-Restriction Fragment Length Polymorphism) method. Tetramethylammonium chloride and glutathione in the enhancer have a synergistic effect, so that the binding capacity of a mismatched primer and a DNA template can be remarkably enhanced, the completeness of a mismatched region at the 3'end of the primer is protected, and non-specific amplification is inhibited while the amplification efficiency is improved.

This invention relates to the field of biomedical technology, specifically to a serum-free and protein-free culture medium and its preparation method for enhancing NK cell expansion and cytotoxic activity. The serum-free and protein-free culture medium comprises a basal medium, an AMPK-HIF1α regulator, immunomodulatory factors, mitochondrial function enhancers, antioxidants, trace elements, and a pH buffer. The AMPK-HIF1α regulator is composed of α-ketoglutarate at a final concentration of 1.4-1.6 mmol / L and AICAR at 0.4-0.6 mmol / L. This culture medium activates the AMPK-HIF1α pathway through precise formulation of α-ketoglutarate and AICAR, and optimizes the metabolic-antioxidant network in synergy with nicotinamide ribose and glutathione, thus solving the industry problem of the incompatibility between expansion and function in serum-free NK cell culture.

The invention belongs to the technical field of veterinary biological products, and particularly relates to a swine fever-porcine pseudorabies bivalent subunit vaccine containing a traditional Chinese medicine immunopotentiator as well as a preparation method and application of the swine fever-porcine pseudorabies bivalent subunit vaccine. The enhancer is prepared by compounding a hypericum perforatum extract and a horse chestnut seed extract, the hypericum perforatum extract and the horse chestnut seed extract are mixed with a classical swine fever virus (CSFV) E2 protein, a pseudorabies virus (PRV) gB protein, a PRV gD protein and an adjuvant to prepare a subunit vaccine, the vaccine can remarkably improve the humoral immunity level and the cellular immunity level excited by the vaccine at the same time, and the vaccine can be used for preparing the vaccine. Specifically, cell factors such as neutralizing antibodies GMT and IFN-gamma are remarkably increased, and the uniformity and stability of immune response are promoted, so that the immunogenicity of the existing swine fever-porcine pseudorabies bigeminy subunit vaccine is effectively improved, and the protection effect of the vaccine is enhanced.

This invention provides a method for improving the antidepressant effect of an NMDAR pore channel blocker, comprising: (1) performing behavioral, pharmacological, or physical measures before or during the plasma half-life of the NMDAR pore channel blocker to open ion channels of a larger proportion of NMDAR molecules in the lateral habenula (LHb); and optionally (2) performing behavioral, pharmacological, or physical measures after administration of the NMDAR pore channel blocker to prevent or reduce the dissociation of NMDAR pore channel blocker molecules from NMDAR. Treatment regimens and drug combinations for effectively treating depression are also provided. This disclosure further provides a drug delivery system comprising an implantable unit capable of controlled, repeatable, and precise in vivo delivery of an NMDAR pore channel blocker, as well as an initiator and / or enhancer, to an LHb region of a subject's brain, thereby achieving improved therapeutic effects.

To provide an intestinal disorder controlling agent, an antiallergic agent, an immunopotentiator and an intestinal adhesion improver of lactic acid bacteria, safely ingestible, inexpensively available and excellent in intestinal adhesion improving action of lactic acid bacteria.SOLUTION: The agent of the present invention contains a flower extract. The flower is a flower of Lythraceae, Asteraceae, Fabaceae, Rosaceae or Iridaceae, and is particularly preferably at least one selected from the group consisting of safflower, pomegranate, kudzu, cherry, chrysanthemum, saffron, peach and rose.SELECTED DRAWING: Figure 1

The application discloses application of tegaserod maleate in preparation of an antibacterial drug synergist, and proves that the tegaserod maleate can produce a synergistic antibacterial effect with a plurality of commonly used antibacterial drugs (including tylosin, tetracycline, enrofloxacin, ampicillin and the like), can significantly enhance the antibacterial activity of the antibacterial drugs on gram-negative bacteria, and reduce the drug resistance of bacteria to the antibacterial drugs; the antibacterial composition composed of the tegaserod maleate and the antibacterial drugs can be used for preparing a drug for treating escherichia coli infection, and the synergistic antibacterial mechanism is mainly to destroy the inner and outer membrane permeability of bacteria, regulate the proton motive force of bacteria, inhibit the activity of bacterial efflux pumps, interfere with the energy metabolism homeostasis of bacteria and induce the bacteria to produce oxidative stress. The application provides a new technical strategy for the treatment of clinical escherichia coli infection, and has important clinical application value and industrialization potential.

The present invention concerns compositions comprising at least one niclosamide compound, such as niclosamide or a pharmaceutically acceptable salt thereof, and at least one permeability enhancer, such as glycerol or dimethylpalmityl-ammonio propanesulfonate (PPS), and their use of such compositions as niclosamide agents. Advantageously, the niclosamide compound is capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 cell membrane in the absence of the permeability enhancer. Compositions, including oral dosage forms, and methods for delivering niclosamide compounds, such as for treatment or prevention of human coronavirus infections, are also provided.

The invention provides a reinforcing agent diluent suitable for an immunohistochemical stainer and a use method, and particularly relates to the technical field of immunodetection. The invention discloses a fresh keeping agent which is prepared from the following components in percentage by mass: 0.1 to 1 percent of Tris, 0.1 to 1 percent of sodium chloride, 0.01 to 0.1 percent of magnesium sulfate, 0.01 to 0.05 percent of Tween-20, 1 to 5 percent of trehalose, 0.01 to 0.05 percent of PC300 preservative, 0.5 to 1.5 percent of bovine serum albumin (BSA), 0.01 to 0.05 percent of casein, 0.01 to 0.05 percent of polyethylene oxide (PEO) and the balance of pure water, wherein the mass fraction of the Tris is 0.1 to 1 percent; the mass fraction of the magnesium sulfate is 0.01 to 0.1 percent; the volume fraction of the Tween-20 is 0.01 to 0.05 percent; the enhancer diluent disclosed by the invention is more suitable for a full-automatic immunohistochemical instrument, and has the advantages of better film preparation effect, higher dyeing intensity and no obvious non-specific coloring.

This invention relates to the field of biochemistry and molecular biology experimental technology, specifically to an SDS-PAGE gel containing hydroxymethyl cellulose, its preparation method, and its applications. The SDS-PAGE gel is polymerized from acrylamide monomer, N,N'-methylenebisacrylamide, sodium dodecyl sulfate, buffer reagent, initiator system, and reinforcing agent. This gel significantly improves mechanical strength, toughness, and tear resistance while maintaining excellent electrophoretic resolution and transparency, effectively solving the problems of traditional gels being fragile, difficult to handle, and easily damaged during transfer processes. The preparation method of this invention is simple and low-cost, and suitable for biochemical research fields such as protein electrophoresis analysis and Western blotting.

The present invention relates to the medical device and ophthalmological industry, as well as related fields such as dermatology and cosmetics, since the formulation includes natural neuroprotective components. The invention describes an iontophoretic delivery of cannabinoid-based formulations designed for ophthalmic conditions, that comprise pharmaceutically acceptable charged vehicles, including but not limited to cationic surfactants, cyclodextrins, nanoparticles and microspheres, emulsions or liposomes, with control the size distribution, potential, osmolality and pH. In a further embodiment of the invention, the intraocular composition proposed further comprises one or more synergistic agents, including but not limited to neuropeptides, exosomes, mitochondrial-derived peptides, complement inhibitors, senolytics, autophagy enhancers, antioxidants, saffron, and non-steroidal anti-inflammatory pharmaceutical drugs with pharmaceutically acceptable charged vehicle.

The invention relates to the technical field of molecular biology, in particular to an anti-inhibition enhanced PCR (Polymerase Chain Reaction) buffer solution which comprises a basic solution and an enhancer, the basic solution is prepared from the following components with final concentrations: MgCl2 with the concentration of 1 to 8 mM, KCl with the concentration of 80 to 200 mM, (NH4) 2SO4 with the concentration of 10 to 50 mM, Tris-HCl with the concentration of 40 to 80 mM and glycerol with the volume ratio of 5 percent; the reinforcing agent is prepared from the following components in final concentration: 8 to 20mM of spermidine and 60 to 140nM of betaine. According to the anti-inhibition enhanced PCR buffer solution, the interference and inhibition of various substances in an excrement sample on a PCR result can be resisted through the synergistic effect of the spermidine reagent and the P betaine reagent in a certain concentration range, and the detection sensitivity is remarkably improved.

The invention discloses an application of sodium bicarbonate in preparation of a tumor immune drug enhancer. The molecular formula of the sodium bicarbonate is NaHCO3. Tumor necrosis factor alpha (TNF-alpha) is used as an anti-tumor drug to treat tumors, however, the anti-tumor efficacy of the TNF-alpha is unpredictable. It is proved that TNF-alpha activates a nuclear factor kappa B (nuclear factor kappa-light-chain-energy active B cells, NF-kappa B) signal channel, inflammatory response is enhanced, tumor cell growth is promoted, and the TNF-alpha can activate a nuclear factor kappa B (nuclear factor kappa-light-chain-energy active B cells (NF-kappa B) signal channel. Under the action of sodium bicarbonate, a TNF-alpha mediated NF-kappa B signal channel is inhibited, a TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1) dependent Necroptosis signal channel is activated, and the death of tumor cells is caused, so that the TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1) depends on the TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1) and the TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1). The prepared medicine contains a medicine excipient or a carrier allowed by a preparation. The invention develops new application of sodium bicarbonate in preparation of medicines for treating tumors. And the medicine is non-toxic to a human body after being administrated in a tumor body. Sodium bicarbonate can be used for preparing a reinforcing agent of TNF-alpha.

The present disclosure provides compounds, compositions, and methods for treating or preventing neurological disorders in a patient. The disclosed methods include administration to a subject suffering from a neurological disorder of a compound disclosed herein.

Disclosed herein is an anti-tumor pharmaceutical composition based on immune checkpoint blockade and use thereof. The anti-tumor pharmaceutical composition comprises: paroxetine hydrochloride, and a T-cell enhancer, wherein the T-cell enhancer is at least one of vitamin E and thymosin. Through a series of in vitro and in vivo experiments, cannabidiol and paroxetine hydrochloride were first found to be capable of effectively reducing the expression of PD-L1 on the tumor cell membrane, thereby blocking the PD-1 / PD-L1 signaling pathway and enhancing the ability of T cells to kill tumor cells. The T-cell enhancer added on this basis can further increase the quantity and activity of T cells, significantly increase the killing ability of T cells after immunosuppression is relieved, and greatly improve the anti-tumor effect of the drug. The components of the pharmaceutical composition used in the present invention, namely, cannabidiol, paroxetine hydrochloride, and vitamin E+thymosin, can exert a synergistic effect and improve the anti-tumor effect.